Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who...

Area of Science:

• Oncology
• Prostate Cancer Research
• Clinical Pharmacology

Background:

• Advanced prostate cancer management is evolving with earlier use of survival-prolonging therapies in metastatic castration-sensitive prostate cancer (mCSPC).
• Taxane chemotherapies are relevant for metastatic castration-resistant prostate cancer (mCRPC), but evidence is limited for their use as first subsequent taxane (FST) after docetaxel intensification (DI) in mCSPC.

Purpose of the Study:

• To compare outcomes of docetaxel and cabazitaxel as FST in mCRPC patients who previously received DI for mCSPC.

Main Methods:

• Retrospective review of 34 patients receiving DI for mCSPC followed by docetaxel or cabazitaxel in mCRPC.
• Primary endpoint: ≥50% PSA response at 12 weeks. Secondary endpoints: Overall survival (OS) from mCSPC diagnosis, Progression-Free Survival (PFS), and OS from FST start date.

Main Results:

• Docetaxel (n=22) and cabazitaxel (n=12) showed activity as FST.
• Patients receiving cabazitaxel had significantly shorter time to FST and OS from mCSPC diagnosis compared to docetaxel.
• No significant differences were observed in PSA response, PFS, or OS from FST start between the two taxanes.

Conclusions:

• Both docetaxel and cabazitaxel are active as FST after DI in mCSPC.
• Docetaxel may be associated with better overall survival from mCSPC diagnosis in this setting.
• Further research is needed due to the study's retrospective nature and small sample size.